Since the Advent of the Transdermal Drug Delivery Technique, There has Been a Continuous Rise in the Market of Transdermal Patches Globally
"Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
- Global Transdermal Patch Market Opportunity: > US$ 15 Billion
- Global Transdermal Patch Clinical Pipeline: 100 Patches In Trials
- Clinical Insight on 66 Commercially/Marketed Transdermal Patches
- Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
- Regional Trends & Market Insight: US, Europe & Asia-Pacific
- Dosage & Price Insight on Transdermal Patch
- Global Transdermal Patch Market Future Prospects
The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026"research report unravels the in-depth analysis and present statistical and non-statistical information related to the current market trends that are prevalent at the global and regional level. In addition to this, the report successfully delivers the information about the sales , dosage and price of the medications that are delivered through this route. Report also discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market and highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
Since the advent of the transdermal drug delivery technique, there has been a continuous rise in the market of transdermal patches globally. The market growth is attributed to the advantages that are associated with the patch technique such as painless and non-invasive administration of the medication, ease of administration and the prolonged activation of the drug inside the body. The availability of large number of transdermal delivery system in the market is continuously proving to be a breakthrough and is currently undergoing by huge commercial success.
Transdermal patches offer many benefits over traditional drug delivery methodologies like pill, powder, or liquid medication. The most important and the fundamental benefit of using patches is the direct-to-bloodstream delivery while bypassing the liver’s metabolic activity. This method of drug delivery is therefore a boon to the patients suffering from hepatic disorders as stress to the liver is simply bypassed. A patient’s body heat activates a patch, prompting it to begin releasing medication through the skin and into the bloodstream. Thus, the innovators have enough good need for development of medications mediating through this drug delivery system.
Transdermal patches can be designed to provide prolonged and controlled release of certain drugs, which can be convenient for pain-relief drugs, nicotine, and hormone products. For instance, granisetron transdermal system is a transdermal patch used to treat chemotherapy-induced nausea and vomiting in a regulated way. The alternative forms - intravenous injections and oral tablets, both pose challenges for patients, whereas transdermal delivery provides a more comfortable and patient-friendly delivery method.
It can be well witnessed that the patch technology is playing its part and the medication in this segment have improved a lot. Clinicians wherever possible and required are more of inclined towards its use; reasons maybe several either the condition of the patient or the extra-long duration of the therapy. The need of transdermal patch drug delivery has already gained momentum and is sure to play its part in the global pharmaceutical market.
Table of Contents
1. Prologue to Transdermal Patch
1.1 Overview of Transdermal Patch
1.2 Relevance of Transdermal Patch
2. Types of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
3. Mechanism of Transdermal Patch Drug Delivery
3.1 Properties of Transdermal Therapeutics
3.2 Components of Transdermal Patch
3.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
3.4 Transdermal Patch v/s Traditional Drug Delivery Methods
4. Global Transdermal Patch Market Insight
4.1 Global Market Scenario
4.2 Regional Market Trends
4.2.1 United States
4.2.2 Europe
4.2.3 Asia Pacific
5. Transdermal Patches for Cardiovascular Diseases - Availability, Dosage & Price Analysis
5.1 Clonidine Transdermal Patch (Catapres–TTS)
5.2 Nitro Glycerin Transdermal Patch
6. Opioid Drug Containing Transdermal Patches - Availability, Dosage & Price Analysis
6.1 Fentanyl Transdermal Patch (Duragesic)
6.2 Buprenorphine Transdermal Patch (Butrans Patch)
7. Transdermal Patches for Neurological Disorders - Availability, Dosage & Price Analysis
7.1 Selegiline Transdermal Patch (Emsam)
7.2 Scopolamine Transdermal Patch (Transderm-Scop)
7.3 Rivastigmine Transdermal Patch (Exelon)
7.4 Methylphenidate Transdermal Patch (Daytrana)
8. Transdermal Patch in Hormonal Therapy - Availability, Dosage & Price Analysis
8.1 Estradiol Transdermal Patch
8.1.1 Alora
8.1.2 Vivelle-Dot
8.2 Testosterone Transdermal Patch (Androderm)
8.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch (Xulane)
9. Transdermal Patches for Other Conditions - Availability, Dosage & Price Analysis
9.1 Nicotine Transdermal Patch (Nicoderm CQ)
9.2 Oxybutynin Transdermal Patch (Oxytrol)
10. Global Transdermal Patch Clinical Pipeline Overview
10.1 By Phase
10.2 By Region/Country
10.3 By Drug Class/Molecule
10.4 By Company
10.5 By Orphan & Fast Track Status
10.6 By Mode of Action
11. Global Patch Clinical Pipeline By Company, Indication & Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-III
11.9 Preregistration
11.10 Registered
12. Marketed Transdermal Patch Clinical Insight
13. Global Transdermal Patch Market Dynamics
13.1 Favorable Market Parameters
13.2 Commercialization Challenges
14. Global Transdermal Patch Market Future Outlook 2026
15. Competitive Landscape
15.1 3M Pharmaceuticals
15.2 Acrux
15.3 Agile Therapeutics
15.4 Allergan
15.5 ANI Pharmaceuticals
15.6 Antares Pharma
15.7 Bayer HealthCare Pharmaceuticals
15.8 Corium International
15.9 Chase Pharmaceuticals
15.10 DURECT Corporation
15.11 Endo Pharmaceuticals
15.12 Fempharm
15.13 Hisamitsu Pharmaceutical
15.14 Immune Pharmaceuticals
15.15 Imprimis Pharmaceuticals
15.16 Ipsen Bioscience
15.17 Johnson & Johnson
15.18 LaSalle Laboratories
15.19 Lavipharm-increase
15.20 MINRAD International
15.21 NeurogesX
15.22 Noven Pharmaceuticals
15.23 NuPathe
15.24 Nuvo Research
15.25 Novartis
15.26 Pain Therapeutics
15.27 ProStrakan
15.28 Purdue Pharma
15.29 Sanofi
15.30 Scilex Pharmaceuticals
15.31 Senju Pharmaceutical
15.32 Somerset Pharmaceuticals
15.33 Teikoku Seiyaku
15.34 Therapeutic Discovery Corporation
15.35 Transdermal Delivery Solutions Corp
15.36 UCB
15.37 Xel Pharmaceuticals
15.38 Zosano Pharma
Figures
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 3-1: Properties of Transdermal Therapeutics
Figure 3-2: Components of Transdermal Patch
Figure 3-3: Types of Permeation Enhancers
Figure 3-4: Schematic Representation of Iontophoresis
Figure 3-5: Mechanism of Scopolamine Transdermal Patch
Figure 3-6: Mechanism of Nicotine Transdermal Patch
Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 3-8: Issues with Traditional Drug Delivery Methods
Figure 3-9: Advantages of Transdermal Patch
Figure 3-10: Consistent Drug Supply by Transdermal Patch
Figure 4-1: Global - Transdermal Patch Market Opportunity (US$ Billion), 2019 - 2026
Figure 4-2: Global - Transdermal Patch Market Share by Product (%), 2019
Figure 4-3: Transdermal Patch Market Size - Global vs. US (US$ Billion), 2019
Figure 4-4: Transdermal Patch Market Size - US vs. Rest of World (%), 2019
Figure 4-5: US - Transdermal Patch Market Opportunity (US$ Billion), 2019 - 2026
Figure 4-6: Global Nicotine Transdermal Patch Market Share - Europe vs. Rest of World (%), 2019
Figure 5-1: Catapres - TTS - Price for 4 Transdermal Film Supply of 0.1mg, 0.2mg & 0.3mg Dose (US$), November’2019
Figure 5-2: Catapres - TTS - Price per Unit of 0.1mg, 0.2mg & 0.3mg Dose Transdermal Patch (US$), November’2019
Figure 5-3: Catapres - TTS – Monthly & annual Treatment cost using 0.1mg dose (US$), November’2019
Figure 5-4: Nitro TD Patch A - Price for 30 Patch supply & Price per Unit (US$), November’2019
Figure 5-5: Minitran & Nitro-Dur - Price for 30 Patch Supply of 0.1mg, 0.2mg, 0.4mg & 0.6mg Transdermal Patches (US$), November’2019
Figure 6-1: Duragesic - Price for 5 Patch Supply of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), November’2019
Figure 6-2: Duragesic - Price per Unit of 12mcg, 25mcg, 50mcg, 75mcg & 100mcg Transdermal Patches (US$), November’2019
Figure 6-3: Butrans - Price for 4 Patch Supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), November’2019
Figure 6-4: Butrans - Price per Unit of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), November’2019
Figure 6-5: Generic Buprenorphine Transdermal Patch - Price for 4 Patch supply of 5mcg, 7.5mcg, 10mcg, 15mcg & 20mcg Transdermal Patches (US$), November’2019
Figure 7-1: Emsam - Price for 30 Patch Supply & Price per Unit of Various Doses of Emsam Transdermal Patches (US$), November’2019
Figure 7-2: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), November’2019
Figure 7-3: Transderm-Scop - Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), November’2019
Figure 7-4: Generic Scopolamine Transdermal Patch - Price for a Supply of 4, 10 & 24 Patches of 1.3mg Transdermal Film (US$), November’2019
Figure 7-5: Generic Scopolamine Transdermal Patch - Price for a Supply of 4, 10 & 24 Patches of 1.5mg Transdermal Film (US$), November’2019
Figure 7-6: Exelon - Price for 30 Transdermal Patch Supply of Exelon (US$), November’2019
Figure 7-7: Generic Rivastigmine Transdermal Patch - Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), November’2019
Figure 7-8: Exelon - Initial & Maintenance Dose for the Treatment of Alzheimer & Parkinson’s Disease
Figure 7-9: Exelon - Monthly & Annual Treatment Cost for Treatment of Alzheimer & Parkinson’s Disease
Figure 7-10: Daytrana - Patent Issue & Expiration Year
Figure 7-11: Daytrana - Price for 30 Transdermal Patch Supply of All Doses (US$), November’2019
Figure 8-1: Alora - Price for a Supply of 8 Patches of Dose 0.025mg, 0.05mg, 0.075mg & 0.1mg (US$), November’2019
Figure 8-2: Alora - Price per Unit of 0.025mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch(US$), November’2019
Figure 8-3: Alora - Recommended Dose for Treatment of vaginal Atrophy & Postmenopausal Osteoporosis (mg/Day Twice in a Week), November’2019
Figure 8-4: Vivelle-Dot - Price for a Supply of 24 Patches of Dose 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg (US$), November’2019
Figure 8-5: Vivelle-Dot - Price per Unit of 0.025mg, 0.0375mg, 0.05mg, 0.075mg & 0.1mg Transdermal Patch (US$), November’2019
Figure 8-6: Recommended Dose for Treatment of vaginal Atrophy, vasomotor Symptoms, & Postmenopausal Osteoporosis (mg/Day), November’2019
Figure 8-7: Androderm - Price for 60 patch Supply & per Unit Price of 2mg Transdermal Patch (US$), November’2019
Figure 8-8: Androderm - Price for 30 patch Supply & per Unit Price of 4mg Transdermal Patch (US$), November’2019
Figure 8-9: Androderm - Recommended Initial & Maintenance Dose For Treatment of Hypogonadism (mg/day), November’2019
Figure 8-10: Ortho Evara - FDA approval & Withdrawal Year
Figure 8-11: Xulane – Price for a Supply of 3 Patches & Price per Unit of 35mcg-150mcg Transdermal Patch (US$), November 2019
Figure 8-12: Xulane - Recommended Schedule for Achieving Birth Control Effect (Days)
Figure 9-1: Nicoderm CQ - Price for a Supply of 14 Transdermal Patches of Doses 7mg, 14mg & 21mg (US$), November’2019
Figure 9-2: Nicoderm CQ - Price per Unit of 7mg, 14mg & 21mg Transdermal Patch (US$), November’2019
Figure 9-3: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients with Consumption More Than 10 Cigarette/Days (mg/day)
Figure 9-4: Nicoderm CQ - Recommended Dose & Treatment Schedule for Patients with Consumption of Less Than 10 Cigarette/Days (mg/day)
Figure 9-5: Nicoderm CQ - Full Treatment Cost for Patient with Daily Consumption of Less than 10 Cigarettes & More than 10 Cigarettes (US$), November’2019
Figure 9-6: Oxytrol - Patent Issue & Expiration Year
Figure 9-7: Oxytrol - Price of 4 Patch Supply & Price per Unit of 3.9mg Transdermal Patch (US$), November’2019
Figure 9-8: Oxytrol - Price of 8 Patch Supply & Price per Unit of 3.9mg Transdermal Patch (US$), November’2019
Figure 10-1: Global - Transdermal Patch Pipeline by Phase (%), 2019 till 2026
Figure 10-2: Global - Transdermal Patch Pipeline by Phase (Number), 2019 till 2026
Figure 10-3: Global - Transdermal Patch Pipeline by Region (%), 2019 till 2026
Figure 10-4: Global - Transdermal Patch Pipeline by Country (Number), 2019 till 2026
Figure 10-5: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2019 till 2026
Figure 10-6: Global - Transdermal Patch Pipeline by Company (%), 2019 till 2026
Figure 10-7: Global - Transdermal Patch Pipeline by Orphan & Fast Track Status (%), 2019 till 2026
Figure 10-8: Global - Transdermal Patch Pipeline by Mode of Action (%), 2019 till 2026
Figure 13-1: Drivers for Transdermal Patch
Figure 13-2: Transdermal Patch Market Commercialization Challenges
Figure 15-1: Acrux Clinical Pipeline
Figure 15-2: Agile Therapeutics Clinical Pipeline
Figure 15-3: Antares Pharma Clinical Pipeline
Figure 15-4: Corium International Clinical Pipeline
Figure 15-5: Durect Corporation Clinical Pipeline
Figure 15-6: Endo Pharmaceuticals Clinical Pipeline
Figure 15-7: Immune Pharmaceuticals Clinical Pipeline
Figure 15-8: Novartis Clinical Pipeline
Figure 15-9: Senju Pharmaceuticals Clinical Pipeline
Figure 15-10: Xel Pharmaceuticals Clinical Pipeline
Figure 15-11: Zosano Pharma Clinical Pipeline
Tables
Table 2-1: Differences between Active & Passive Transdermal Patches
Table 4-1: Transdermal Patches for Various Disease Indications
Table 8-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 8-2: Butrans - Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 9-1: Daytrana - Dose Increment Pattern for Treatment of ADHD
Table 15-1: Pain Therapeutics Clinical Pipeline
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3M Pharmaceuticals
- Acrux
- Agile Therapeutics
- Allergan
- ANI Pharmaceuticals
- Antares Pharma
- Bayer HealthCare Pharmaceuticals
- Corium International
- Chase Pharmaceuticals
- DURECT Corporation
- Endo Pharmaceuticals
- Fempharm
- Hisamitsu Pharmaceutical
- Immune Pharmaceuticals
- Imprimis Pharmaceuticals
- Ipsen Bioscience
- Johnson & Johnson
- LaSalle Laboratories
- Lavipharm-increase
- MINRAD International
- NeurogesX
- Noven Pharmaceuticals
- NuPathe
- Nuvo Research
- Novartis
- Pain Therapeutics
- ProStrakan
- Purdue Pharma
- Sanofi
- Scilex Pharmaceuticals
- Senju Pharmaceutical
- Somerset Pharmaceuticals
- Teikoku Seiyaku
- Therapeutic Discovery Corporation
- Transdermal Delivery Solutions
- UCB
- Xel Pharmaceuticals
- Zosano Pharma
